CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,085 enrolled / 1,085 target
Drug / intervention
Insulin icodec +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04760626
NCT04760626Phase 3CompletedMonitor (16.9/mo)Completion was 46mo ago

Effectiveness and Safety of Once Weekly Insulin Icodec Used With DoseGuide Versus Once Daily Basal Insulin Analogues in an Insulin naïve Type 2 Diabetes Population in a Clinical Practice Setting

Novo Nordisk A/S·interventional·Posted Feb 18, 2021·Updated Jun 16, 2026

In Brief

A Phase 3 clinical trial evaluating Insulin icodec, Insulin Glargine 100U/mL, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 1,085 participants across 311 sites in 10 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

This study compares insulin icodec to different daily insulins in people with type 2 diabetes. The study will look at how well insulin icodec taken once weekly controls blood sugar compared to the insulins taken once daily. Participants will either get insulin icodec, that participants will have to inject once a week on the same day of the week, or a marketed insulin, that participants will have to inject once a day. Which treatment participants get is decided at random. The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach. Participants will measure their blood sugar every day. Participants will get a study phone to record safety data in the electronic diary (eDiary). If participants get a daily insulin they will record their insulin doses in the eDiary. If Participants get weekly insulin icodec, participants study phone will also have the DoseGuide App. The DoseGuide App gives dose recommendations based on their blood sugar and previous doses. Participants will record their insulin doses in the DoseGuide App. The study will last for about 1 year and 2 months. Participants will have 8 planned clinic visits with the study doctor. More visits will be planned to meet individual needs. At 6 clinic visits participants will have blood samples taken. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBulgaria, Canada, Germany, Greece, Hungary, Poland, Puerto Rico, Serbia, Turkey (Türkiye), United States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedFeb 18, 2021
Enrollment StartMar 1, 2021
Primary CompletionAug 12, 2022
Study CompletionAug 29, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.4 years ago

Arms & Interventions

Insulin icodec with DoseGuideexperimental

Participants randomised to insulin icodec will use insulin icodec with the DoseGuide App to guide their titration.

Drug: Insulin icodec
Once daily basal insulin analoguesactive_comparator

Participants randomised to basal insulin analogue injections once daily

Drug: Insulin Glargine 100U/mLDrug: Insulin DegludecDrug: Insulin Glargine 300U/mL

Interventions

Insulin icodecdrug

Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.

Insulin Glargine 100U/mLdrug

Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.

Insulin Degludecdrug

Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.

Insulin Glargine 300U/mLdrug

Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.